Search

Search Constraints

You searched for: Author/Creator Munshi, Nikhil C.

Search Results

1. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma. (8th May 2018)

2. A Phase IB multicentre dose‐determination study of BHQ880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal‐related events. (19th August 2014)

3. A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. (8th January 2015)

4. C‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma. (15th April 2020)

7. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations. (June 2015)

8. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. Issue 27 (20th September 2022)

10. Next‐generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. Issue 19 (23rd May 2017)